Targeting cancer’s genetic bandoliers
One way tumors evolve beyond the clutches of cancer-killing drugs is by tapping a spare genetic arsenal that keeps them alive. A startup that just raised $46 million has a plan to cut off the resupply.
Boundless Bio, funded by a syndicate including Arch Venture Partners, is focused on extrachromosomal DNA, circles of genetic material that float within cancer cells and offer a just-break-glass survival mechanism for tumors under attack. The idea is to target DNA and disarm cancers that have outfoxed standard treatments.
It’s early days yet, and Boundless has years of work before it’ll be ready for human trials, but the founders believe they’ve hit on an idea that can subvert the concept of precision medicine.
Read more.
Boundless Bio, funded by a syndicate including Arch Venture Partners, is focused on extrachromosomal DNA, circles of genetic material that float within cancer cells and offer a just-break-glass survival mechanism for tumors under attack. The idea is to target DNA and disarm cancers that have outfoxed standard treatments.
It’s early days yet, and Boundless has years of work before it’ll be ready for human trials, but the founders believe they’ve hit on an idea that can subvert the concept of precision medicine.
Read more.
.png)
No hay comentarios:
Publicar un comentario